Table 1 Patient demographics

Total enrolled

9

Median (range) age (years) at study enrollment

46 (29–65)

 ER+/HER2+

7

 ER–/HER2+

2

Median ECOG performance status

0 (0–1)

Prior lines of chemotherapy in the metastatic setting, median (range)

3 (2–6)

Prior lines of endocrine therapies in the metastatic setting, median (range)

1 (1–3)

Prior number of anti-HER2 agents in the metastatic setting, median (range)^a

3 (2–4)